Articles tagged with Colorectal Cancer
Researchers have developed a highly sensitive method to detect even earlier stages of colorectal cancer by analyzing metabolites in blood plasma. The new screening method exceeds 96% sensitivity and specificity, confirming its effectiveness even for early-stage patients.
Researchers have identified specific types of bacteria that are abundant in individuals with colorectal cancer. Using a combination of markers, scientists anticipate the development of a noninvasive, sensitive clinical diagnostic test. The study confirms previously reported bacteria and identifies new ones associated with the disease.
Colorectal cancer rates in New Zealand are increasing, particularly among younger adults. The study found a significant rise in rectal cancer incidence in men and women under 50, while older adults saw an increase in proximal cancer incidence.
A phase II trial found that adding rice bran to the diet of colorectal cancer survivors increased microbiome richness and diversity. The study also showed reduced cell growth in treated cells when participants consumed high amounts of rice bran.
Researchers have developed a new humanized mouse model of colorectal cancer, allowing them to test immunotherapies and potential combination treatments. The model has shown promise in preclinical studies, including the successful activation of the immune system against cancer cells.
The Case Comprehensive Cancer Center has been named to a new national colorectal cancer dream team, comprising scientists and clinicians from top institutions. The team will test a promising new therapy for the first time in human patients, combining glutaminase inhibitor CB-839 with chemotherapy medication capecitabine.
A study from Penn State College of Medicine found that a patient's confidence in scheduling and conducting their part in colorectal screening methods is crucial in determining their intention to get screened. Self-efficacy emerged as the most important factor, reflecting knowledge, experience, or understanding of the testing options.
Researchers found that individuals with blindness, intellectual disability, or spinal cord injury are less likely to receive recommended colorectal screenings. The study's findings emphasize the importance of increased awareness and advocacy efforts to ensure all individuals are screened appropriately for this preventable cancer.
Hispanics have a higher burden of poor health-related quality of life (HR-QoL) compared to white and black patients. Meanwhile, Hispanics experience longer median survival times, averaging 85.4 months, followed by blacks at 47.8 months and whites at 43.2 months.
Researchers have identified a new molecular target, OR51B4 olfactory receptor, in colorectal cancer cells, which can be activated by the odorant troenan. This activation leads to inhibition of tumour growth, slowing down cell proliferation and increasing apoptosis.
Researchers developed a predictive risk model combining genetic and lifestyle information to classify population into groups according to colon cancer risk. Lifestyle influences cancer risk more than genetics, making it a modifiable factor in disease prevention.
Researchers at Case Western Reserve University discovered changes in specific regions of DNA that 'enhance' harmful gene expression to promote tumor growth. These recurrent changes in DNA activate genes involved in colorectal cancer progression.
A recent study found a significant increase in colorectal cancer incidence rates among young adults, including those in their early 50s. Rectal cancer rates are rising even faster, with three in ten diagnoses now in patients under 55.
A large review found strong associations between obesity and risk of certain cancers, including oesophageal, bone marrow, colon, rectal, biliary tract system, pancreatic, endometrial, and kidney cancers. The study calls for more research to confirm these findings.
A recent study found that normal-weight postmenopausal women who are metabolically unhealthy have a significantly increased risk for colorectal cancer compared to those who are metabolically healthy. This highlights the importance of assessing metabolic health status in women, which can be done using standard clinical tests.
A recent study among over 1000 colorectal cancer patients found that about 10% carry mutations associated with increased cancer susceptibility. The research recommends genetic testing for all patients to identify these risks and prevent future cases. This expanded approach could also benefit at-risk family members by providing earlier ...
A new study found that a 'prudent' diet rich in whole grains and fiber can lower the risk of colorectal cancer by altering the balance of microorganisms in the digestive tract. Participants with tumors containing Fusobacterium nucleatum had a sharply lower risk, but those without the bacteria received no extra protection.
A study published in Health Affairs found that the Affordable Care Act resulted in an 8% increase in early-stage colorectal cancer diagnoses among U.S. seniors aged 65 and older, but had no distinguishable effect on breast cancer diagnoses over the same time period.
A new study reveals significantly better outcomes for patients with metastatic colorectal cancer when combining vemurafenib with standard treatments. The three-drug combination improved progression-free survival rates and tumor response rates compared to traditional therapies.
A study by Osaka University reveals that colorectal cancer cells can survive under glucose-depletion conditions by maintaining TCA cycle activity and ATP production. Key proteins GLUD1 and SLC25A13 play pivotal roles in nutritional stress and are associated with tumor aggressiveness.
A recent study led by Georgia State University researcher found that living in segregated communities can affect colorectal cancer diagnosis timing. Residents of highly segregated Asian communities are more likely to receive late diagnoses, while those in African American communities are less likely.
Researchers identified MMP9 as a tumor suppressor role in colitis-associated cancer (CAC), which is driven by chronic inflammation. The study found that MMP9 suppresses tumors by activating the MMP9-Notch1-ARF-p53 axis pathway.
The new Special Issue addresses topics in epidemiology, basic science, and policy, providing reliable information on digestive cancers in Latin America. Key findings include the rising incidence of gastric cancer and the need for awareness, with five articles from experts in the region.
Researchers found that vitamin E and selenium supplements did not prevent colorectal adenomas in a large-scale study. The findings suggest that these antioxidants have no evidence of preventing cancer.
Research suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) can prevent the recurrence of advanced neoplasia after polyp removal, with ibuprofen showing superior benefits over aspirin or supplements. However, the choice of NSAID should be individualized based on patient risk factors and health considerations.
The ColoCare study, led by Huntsman Cancer Institute, aims to identify elements that impact colorectal cancer patients' survival and recovery. The study analyzes health and lifestyle factors to predict patient outcomes and determine the most effective treatments.
A study of 450 patients found 72 with 75 unique gene mutations, affecting 16 percent of younger-onset CRC cases, suggesting genetic counseling and multigene panel testing for early-onset patients
A statewide colorectal cancer screening study found that 16% of patients diagnosed under age 50 have an inherited genetic mutation increasing their cancer risk. The study identified a broad spectrum of mutations in early-onset colon cancer patients, including those linked to breast cancer risk.
A study led by Dr. Steven A. Rosenberg identified a method to target the cancer-causing protein produced by a mutant form of the KRAS gene, leading to cancer regression in a patient with colorectal cancer. The treatment involved infusing tumor-infiltrating lymphocytes into the patient, which recognized and attacked the mutated cells.
A four-week prehabilitation program has shown promising results in preparing cancer patients for surgery by improving their physical fitness and reducing recovery time. The study involved 116 colorectal cancer patients who underwent the program before undergoing surgery.
A metabolite called D-2-hydroxyglutarate (D-2HG) has been identified as a promising target for future cancer therapies due to its ability to promote cancer cell transformation and increase the likelihood of tumor spread in colorectal cancer patients.
A recent study published in Cancer Research found that emulsifiers in processed foods can alter the gut microbiota in mice, leading to increased tumor development and inflammation. The study suggests that dietary emulsifiers may be partially responsible for the increasing incidence of colorectal cancer worldwide.
A new analysis of 1981 patients with lower gastrointestinal symptoms found that the new criteria would miss nearly 20% of colorectal cancers. The study suggests that alarm features indicative of colorectal cancer are common among the general population, limiting their accuracy in predicting a diagnosis.
Scientists have discovered a metabolic fingerprint in feces that matches changes in tumor tissues, suggesting a potential new diagnostic tool for early detection of colorectal cancer. The method uses ultrasensitive technology to identify molecules in the feces of mice and humans, with promising results for noninvasive testing.
The new evidence-based clinical guideline from the National Osteoporosis Foundation and American Society for Preventive Cardiology says that calcium with or without vitamin D intake should be considered safe for generally healthy adults. Obtaining calcium from food sources is preferred, but supplements can be used to address dietary sh...
A Phase 2 study of a novel colonoscopy prep found it to be at least as effective and safe as existing products, while offering higher levels of patient satisfaction and preference. The investigational treatment allows patients to eat solid food bars and drink palatable beverages, leading to nearly four times more recommendations.
A UA-led study found selenium supplementation significantly increased the risk of developing type 2 diabetes, casting doubt on its effectiveness for preventing colorectal cancer. The study suggests a reevaluation of selenium supplements' use due to this potential adverse effect.
Nintedanib significantly improves median progression-free survival compared to placebo, with disease control improved by 26% compared to 11% in the placebo group. However, overall survival did not differ between the two groups.
A new study suggests health-care providers support routine testing of colorectal tumors to identify individuals with Lynch Syndrome. However, there is a lack of consensus on whether patients should be allowed to opt out of the test, which could determine their risk of developing cancer.
Researchers at Boston University School of Medicine have discovered a new role of the protein c-Cbl in degrading ?-catenin, a vital protein involved in cancer initiation. This finding could lead to new strategies to suppress Colorectal Cancer growth and improve patient survival.
Researchers at IDIBELL discovered that tumor microenvironment triggers processes to protect tumor cells from conventional chemotherapy. The presence of certain molecules slows down cell cycle and activates proteins minimizing treatment effectiveness.
Researchers at Stanford University School of Medicine discovered that retinoic acid levels play a critical role in suppressing colorectal cancer. Higher levels of the metabolite were found in mice and human tissues with less severe intestinal inflammation, suggesting new ways to prevent or treat colorectal cancer.
A novel small-molecule Wnt inhibitor named NCB-0846 has been discovered with potential to eradicate colorectal cancer stem cells. The inhibitor targets the Traf2- and Nck-interacting kinase (TNIK) regulatory component of the Wnt signaling pathway, blocking its signal even in colorectal cancer cells with APC gene mutations.
The American Gastroenterological Association (AGA) has launched a new PatientINFO Center to provide high-quality, readable information on colorectal cancer. The center addresses gaps in existing resources, offering detailed information on screening options, risk factors, and prevention strategies.
Researchers found that colorectal tumors have different regions with varying levels of epigenetic changes, which relate to the tumor's growth rate and aggressiveness. This heterogeneity can be used to predict prognosis and treatment resistance.
A recent study by the University of California - Davis Health found that Hispanic men in California have lower rates of screening for colorectal cancer compared to white men. The study suggests that increased screening can help reduce the incidence and mortality rates of the disease among this population.
A new study reveals that fusobacteria use a special sugar-binding protein to stick to developing colorectal polyps and cancers. This mechanism may inform ways of blocking fusobacteria from homing in on tumors, and could potentially prevent colorectal cancer progression.
A study at Columbia University's Mailman School of Public Health found that obesity prevalence increased from 22% to 32% among cancer survivors between 1997 and 2014. Colorectal and breast cancer survivors, as well as non-Hispanic blacks, were particularly affected.
Case Western Reserve University researchers identified why colorectal cancer cells depend on glutamine and developed a way to starve them. In a mouse model, exposing tumors with PIK3CA mutation to glutamine metabolism inhibitors suppressed tumor growth, providing a promising new therapeutic avenue for colorectal tumors.
The ESMO consensus guidelines reflect a personalized treatment approach to managing metastatic colorectal cancer, incorporating molecular markers and patient selection. The guidelines aim to improve outcomes by providing evidence-based recommendations for treatment options.
Researchers have developed a blood-based screening test to gauge colon cancer recurrence and monitor chemotherapy effects. The test detects tumor DNA fragments in the blood, which can identify patients at high risk of relapse and track treatment efficacy.
Researchers identified genetic mutations in immune system genes that may lead to synchronous colorectal cancer, a rare type of bowel tumor. The study found that these patients have inherited damaging mutations that can cause an inflammatory environment in the gut, increasing the frequency of independent cancer-initiating events.
MABp1 improves symptoms, reduces inflammation and increases clinical response rate by 76%, with a 3x longer survival time for responders. Excellent safety and tolerability were also observed.
A new study reveals that only 8% of patients with large, apparently benign polyps have cancer, suggesting advanced endoscopic treatments like EMR and ESD as viable options. This finding could improve patient outcomes, reduce complications, and lower healthcare costs.
A phase I trial found that combining anti-PD-L1 immunotherapy with a MEK inhibitor achieves partial responses and is well-tolerated in patients with microsatellite-stable metastatic colorectal cancer. The combination was shown to increase the number of active immune cells in tumors, leading to improved responses.
A team of scientists has developed a computational method to map cancer progression, which offers new insights into the factors that spur this affliction. The researchers used gene sequencing data to create a model that predicts how a tumor's genomes will change over time.
Consistent reductions in cancer incidence and mortality were observed with adherence to cancer prevention guidelines. These guideline adherence showed a significant reduction of 10-45% in all cancer incidence and 14-61% in all cancer mortality. The review also found consistent reductions in breast, endometrial, and colorectal cancers.
Researchers identified TIP60 as an enzyme required for HIF1A activity in human colorectal cancer cells, showing its potential as a target for cancer treatment. The study also revealed the molecular mechanisms by which TIP60 promotes HIF1A activity and highlights the importance of basic research in cancer discovery.
Researchers developed pretargeted radioimmunotherapy, combining an anti-GPA33 antibody with radionuclide agents to deliver radiation directly to tumors. In mouse models, the technique achieved complete remission of colorectal cancer without collateral toxicity.
A study found that about 40% of Hispanic adults with colorectal cancer used complementary and integrative health practices. Women were more likely to have used these practices than men, according to the study published in The Journal of Alternative and Complementary Medicine.